Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
March 3, 2026
Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program with Commercial Lifileucel.
AD
Amrita Desai
Oregon Health & Science University
CV
Cristian D. Valenzuela
Oregon Health & Science University
MB
Matthew Blackburn
Oregon Health & Science University
See all
Key Points
Therapeutic outcomes demonstrate significant improvement in melanoma cases treated with lifileucel.
Data indicates a median overall survival of 21 months in patients undergoing this therapy.
Observational analysis of patients treated at a single center provides valuable insights into the therapy's efficacy.
Findings support the potential of lifileucel to enhance immune responses against melanoma.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program with Commercial Lifileucel. | Synapse
Cite This Study
Copy
Desai et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7607cc6e9836116a2d45e
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.248